Menu
Recruiting NCT05208164

My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes

No phase Interventional Type 2 Diabetes Sleep Stress

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Mindfunlness Meditation.
Who it may be relevant to
Registry conditions: Type 2 Diabetes, Sleep, Stress. Basic parameters: 21 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

My ESSENCE - Mindfulness to Reduce Stress, Improve SIeep, and Reduce Cardiovascular Risk in African-Americans With Type 2 Diabetes

Overview

The proposed research and training will allow Dr. Alana Biggers to obtain critical research skills and study a mindfulness meditation program designed to improve sleep and reduce stress in African-American adults with diabetes. If effective, this program may reduce the risk of cardiovascular disease among African-Americans with type 2 diabetes who are at high risk of cardiovascular disease.

Detailed description

African-Americans have disproportionate rates of cardiovascular disease (CVD) in the US. African-Americans with type 2 diabetes (T2DM) have twice the risk than non-Hispanic whites for developing CVD. Poorer sleep and greater chronic psychological stress may contribute to this additional risk. Consequently, African-Americans have worse glycemic control among those with diabetes and higher CVD risk. One promising approach to improving CVD risk in African-Americans is mindfulness meditation (MM). MM can potentially reduce cardiovascular risk through attention control, emotional regulation, and self-awareness. The overall purpose of this K01 training grant is for Dr. Alana Biggers to obtain research training and develop skills needed to become an independent investigator, and use those skills to adapt and evaluate an established MM curriculum. The specific aims are to: (1) adapt and refine an established MM curriculum for African-Americans with T2DM and incorporate text messaging; (2) conduct an 8-week, pilot randomized, controlled trial of the adapted curriculum with up to 100 African-Americans with T2DM(goal of 68 for study completion); and (3) explore the impact of the intervention on cardiometabolic risk factors (blood pressure, glycosylated hemoglobin, and lipid profile) and inflammatory biomarkers (C-reactive protein, interleukin-6, and tumor necrosis factor α). Primary outcomes will include sleep quality and perceived stress evaluated at baseline, 8, and 16 weeks. The proposed research design consists of a pilot study, utilizes mixed-methods research, and involves both primary data collection and analysis. Participants will be randomized 1:1 to either the MM intervention or control. Patients will be assigned to fill cohorts so that those in intervention group will attend MM classes together. A cohort represents a group of 10-12 subjects enrolled within a 1-month time period. MM classes will guide participants in learning and implementing MM practices over 8 weeks. Data collection will occur at baseline, 8 weeks (completion of MM sessions), and 16 weeks. The 16-week data assessment will evaluate MM practice beyond the MM class structure to assess for sustainability.

This K01 training grant will provide Dr. Biggers career-building activities to further develop skills and a knowledge base in quantitative and qualitative methodology, health disparities research, and mobile health (mHealth)/behavioral health strategies in minority populations. With the guidance of an interdisciplinary mentorship team and institutional support, Dr. Biggers will receive the necessary assistance and training to work toward her long-term career goal of being an independent researcher with expertise in health disparities, mixed-methods, and mHealth behavioral research.

Interventions

  • Behavioral Mindfunlness Meditation
    Sleep monitoring, mental health promotion and active enrollment/engagement in self-described coping mechanisms

Primary outcome measures

  • Sleep Quality [Time frame: Change from baseline at 8 and 16 weeks.]
  • Perceived Stress [Time frame: Change from baseline at 8 and 16 weeks.]
  • Sleep Disturbances [Time frame: Change from baseline at 8 and 16 weeks]
  • Sleep Impairment [Time frame: Change from baseline at 8 and 16 weeks]
Secondary outcome measures (3)
  • Cardiovascular Risk [Time frame: Change from baseline at 8 weeks]
  • Hemoglobin A1c [Time frame: Change from baseline at 8 weeks.]
  • Inflammatory Markers [Time frame: Change from baseline at 8 and 16 weeks]

Eligibility criteria

Inclusion criteria

  • Self-identifies as African American or Black
  • Diagnosis of type 2 diabetes
  • Valid address in greater Chicagoland area
  • Mobile phone with unlimited text-messaging
  • Mobile device (smartphone, tablet, or computer) with the ability to connect to the internet if remote online delivery
  • Availability to participate in mindfulness class either in-person or online
  • Age 21-75

Exclusion criteria

  • Untreated obstructive sleep apnea (OSA)
  • Severe insomnia, narcolepsy, or REM sleep related disorder
  • Major cognitive impairments or psychiatric disorder
  • Alcohol or drug abuse
  • Limited English proficiency
  • Inability to send/receive text messages
  • Currently engaging in mindfulness practice

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Health services research

Study locations

United States · 1 center
  • University of Illinois at Chicago — Chicago

Identifiers

NCT: NCT05208164 · 2019-1433 · 1K01HL149775

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗